Background: Epidemiological surveillance of a nursing diagnosis is an approach anchored in a post-modern epidemiology focused on a person’s health disease responses. Regarding public health priorities, the population where our study occurred had as a priority problem arterial hypertension. Related to this chronic disease, nursing diagnoses about health disease responses in primary healthcare has, as a major focus, Therapeutic Regimen Management. Our aim was to study the nursing diagnosis in this issue from an epidemiological approach. Methods: A descriptive study from an epidemiological approach was developed, analyzing nursing diagnoses in hypertensive patients. Results: We found 17.7% of undiagnosed patients and better diagnoses in patients with complications than in those without complications. Conclusions: Nursing records need to be improved in order to promote more robust studies in the post-modern epidemiology for the future.
Objectives: In patients with chronic spontaneous (CSU), who remain symptomatic despite the use of anti-histamines, omalizumab significantly improved outcomes in three Phase III randomized clinical trials. We aimed to identify characteristics that could predict the speed of symptoms recurrence after treatment discontinuation, and explore the potential relationship between the timing of response onset and the speed of symptoms recurrence in CSU patients treated with omalizumab. MethOds: This exploratory analysis used pooled patient-level data from two Phase III RCTs: ASTERIA I (n = 319; 6 injections of omalizumab 75, 150, 300 mg or placebo every 4 weeks) and ASTERIA II (n = 323; 3 injections of omalizumab 75, 150, 300 mg or placebo every 4 weeks). The follow-up periods lasted for 16 weeks. Twice daily Urticaria Activity Score summed over 7 days (UAS7TD) was used to assess disease activity and response to treatment. Least absolute shrinkage and selection operator (LASSO) regularization regression model was used to select variables that were predictive of symptom recurrence over the 16 week follow-up period. Least squares linear regression with prediction intervals was used to estimate the recurrence probability for each patient based on the selected variables. Results: The LASSO model identified two parameters that can jointly predict a probability of a patient's symptoms recurrence after treatment discontinuation: (a) Speed of treatment response quantified by the Area Above the Curve (AAC) of the UAS7TD over the initial 4-week treatment period and (b) baseline UAS7TD. Most of the predictive performance was attained after 4 weeks, and optimum performance was achieved after 7 weeks of treatment. cOnclusiOns: It may be possible to estimate the probability of symptoms recurrence after discontinuing omalizumab treatment in patients with CSU, based on baseline UAS7TD and early response to omalizumab treatment. A better understanding of the potential clinical relevance of this exploratory analysis is needed.Objectives: Lyme Borreliosis (LB) and tick borne encephalitis (TBE) are endemic in Central and Eastern Europe where they are a public health concern. Effective preventive strategies for these tick borne diseases include vaccines which are currently available for TBE and in final phase clinical trials for LB. The study aims to construct and validate a mathematical model set in high risk populations that will simultaneously present a natural course of both LB and TBE. MethOds: Natural histories of LB and TBE were defined through clinically relevant disease phases. Literature was reviewed for probabilities of each disease phase through time and quality of life reported for LB and TBE patients. For population and model validation we used Slovenian data as the country has one of the highest risks for both diseases and satisfactory surveillance system. Age specific incidence rates, rates of disease complications and general mortality rates were extracted. Results: A Markov model that synthesizes LB and TBE courses was create...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.